Retrospective Study
Copyright ©The Author(s) 2022.
World J Gastrointest Oncol. Apr 15, 2022; 14(4): 897-919
Published online Apr 15, 2022. doi: 10.4251/wjgo.v14.i4.897
Table 1 Baseline characteristics of the patients
Characteristics
INFa (n = 183)
INFb (n = 331)
INFc (n = 448)
Sex
Male133 (72.7)248 (74.9)308 (68.8)
Female50 (27.3)83 (25.1)140 (31.2)
Age (yr)58.81 ± 9.5959.30 ± 9.7357.06 ± 10.55
Borrmann type
0-131 (16.9)51 (15.4)21 (4.7)
262 (33.9)105 (31.7)104 (23.2)
374 (40.4)138 (41.7)242 (54.0)
4-516 (8.8)37 (11.2)81 (18.1)
Tumor location
Lower third156 (85.2)227 (68.6)329 (73.4)
Middle third21 (11.5)64 (19.3)75 (16.8)
Upper third4 (2.2)33 (10.0)31 (6.9)
Entire stomach2 (1.1)7 (2.1)13 (2.9)
Tumor size (mm)44.40 ± 24.8553.06 ± 25.7856.31 ± 27.38
pTNM stage
I72 (39.3)70 (21.1)36 (8.0)
II60 (32.8)127 (38.4)137 (30.6)
III51 (27.9)134 (40.5)275 (61.4)
Histological type
Well and medium differentiation112 (61.2)149 (45.0)126 (28.1)
Poor differentiation46 (25.1)88 (26.6)207 (46.2)
Others25 (13.7)94 (28.4)115 (25.7)
mLNR0.09 ± 0.160.12 ± 0.170.19 ± 0.22
Vascular infiltration
No137 (74.9)231 (69.8)317 (70.8)
Yes46 (25.1)100 (30.2)131 (29.2)
Nerve infiltration
No123 (67.2)198 (59.8)251 (56.0)
Yes60 (32.8)133 (40.2)197 (44.0)
Postoperative chemotherapy
Yes58 (31.7)90 (27.2)167 (37.3)
No125 (68.3)241 (72.8)281 (62.7)